Welcome to our dedicated page for TNF Pharmaceuticals SEC filings (Ticker: TNFA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can stretch past 300 pages, packed with protocol diagrams, FDA correspondence and stock option tables. TNF Pharmaceuticals鈥� newest 10-K and 10-Q are no different; understanding how MyMD-1 and Supera-CBD trials affect cash runway or dilution is a real challenge.
That鈥檚 why Stock Titan pairs every document with AI-powered summaries that translate scientific jargon into clear takeaways. Need the "TNF Pharmaceuticals quarterly earnings report 10-Q filing" to see updated R&D spend? Or a quick scan of "TNF Pharmaceuticals 8-K material events explained" after an FDA Fast Track announcement? It鈥檚 all here, updated in real time from EDGAR.
Our coverage spans every form investors ask for:
- "TNF Pharmaceuticals annual report 10-K simplified" highlights trial milestones and liquidity.
- "TNF Pharmaceuticals insider trading Form 4 transactions" and "TNF Pharmaceuticals Form 4 insider transactions real-time" reveal when executives trade around data readouts.
- "TNF Pharmaceuticals proxy statement executive compensation" clarifies incentives tied to clinical success.
Each filing comes with side-by-side metrics, keyword search, and alert tools, making "understanding TNF Pharmaceuticals SEC documents with AI" straightforward. Whether you鈥檙e tracking segment expenses, patent disclosures, or "TNF Pharmaceuticals earnings report filing analysis," our platform delivers the context professionals need鈥攚ithout the slog through dense biotech language or PDFs.
TNF Pharmaceuticals (TNFA) reported significant operating losses and financing activity for the six months ended June 30, 2025. The company recorded a net loss of $19,365,689 (six months) and $2,920,938 (three months) with research and development expenses of $2,418,985 (six months) and $873,472 (three months). Preferred stock dividends materially reduced results, totaling $1,789,865 (six months) and $976,369 (three months).
The filing discloses heavy financing through multiple preferred series and warrant issuances, conversions and anti-dilution adjustments (Series F, F-1, G and D), and large share issuances during the period. The company reports negative operating cash flows and states substantial doubt about its ability to continue as a going concern without additional capital. The company also received a Nasdaq notice regarding a minimum bid price deficiency and has a compliance period to regain the $1.00 minimum bid requirement.
FAQ
What is the current stock price of TNF Pharmaceuticals (TNFA)?
What is the market cap of TNF Pharmaceuticals (TNFA)?
